
    
      Screening and follow-up cardiac magnetic resonance imaging (CMR) protocols for diagnosis of
      cardiotoxicity will be conducted in patients with breast cancer who have received or are
      planned to receive treatment for breast cancer. The protocol will include T1 and T2 mapping
      and cine imaging of the LV myocardium.
    
  